PRPO

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Wall Street analysts forecast PRPO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRPO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Precipio Inc revenue for the last quarter amounts to 6.77M USD, increased 29.91 % YoY.

Precipio Inc. EPS for the last quarter amounts to -0.05 USD, decreased -88.10 % YoY.

Precipio Inc (PRPO) has 54 emplpoyees as of December 16 2025.

Today PRPO has the market capitalization of 42.15M USD.